

Special Issue

Radiopharmaceuticals and Nanotechnology

Message from the Guest Editors

In this special issue of *Pharmaceuticals*, we aim to provide exciting insights into state-of-the-art research as well as future developments in the field of nanotechnologies for radiation-based diagnosis and treatment. We invite transdisciplinary teams to submit papers (full research papers, short communications and review) covering a range of topics in the field including, but not limited to:

- The design and synthesis of novel nanomaterials/tracers;
- The use of nanotechnology for multi-modal applications including targeted drug delivery, imaging or radiation therapy;
- Characterization and modelling of the pharmacokinetics/pharmacodynamics of radiopharmaceuticals and nano-objects;
- New in vivo (pre)-clinical validations of nanomaterials and radiopharmaceuticals for the treatment of cancer and other diseases;
- Nanotechnology-enhanced dosimetry of radiotherapy and radiopharmaceutical therapy.

Guest Editors

Dr. Sébastien Penninckx

Medical Physics Department, Jules Bordet Institute, 90 Rue Meylemeersch, B-1070 Brussel, Belgium

Dr. Céline Mirjolet

Preclinical Radiotherapy and Radiobiology Research Team, PIRP, INSERM-1231, Centre Georges François Leclerc, Unicancer, 1 rue Pr Marion, 21079 Dijon, France

Deadline for manuscript submissions

closed (25 February 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/171461

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)